Hepatocellular Carcinoma
Conditions
Keywords
Hepatic arterial infusion chemotherapy, Sorafenib
Brief summary
To evaluate safety and efficacy of combined hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, 5-fluorouracil and leucovorin and sorafenib in hepatocellular carcinoma (HCC) refractory to transarterial chemoembolization(TACE)
Detailed description
In most current guidelines, sorafenib is considered as the second-line treatment for patients with transarterial chemoembolization(TACE) failure or refractoriness.However,the median overall survival of those treated with sorafenib monotherapy was 16.4 to 24.7 months. Whether combining sorafenib with hepatic arterial infusion chemotherapy(HAIC) of oxaliplatin,5-fluorouracil and leucovorin is safe, well tolerated, and efficacious remains unknown, with no prospective clinical data currently available.The investigators therefore conducted a prospective and randomized phase II trial to compare the safety and efficacy of HAIC with sorafenib in patients refractory to TACE
Interventions
DRUGHAIC of FOLFOX
administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
DRUGSorafenib
administration of Sorafenib
Sponsors
Guangzhou No.12 People's Hospital
Kaiping Central Hospital
Sun Yat-sen University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* TACE failure or refractoriness based on the Liver Cancer Study Group of Japan (LCSGJ) criteria, including appearance of vascular invasion or two or more consecutive insufficient responses of the intrahepatic lesion; * Except for TACE, patients have received no previous anti-tumor treatment; * The diagnosis of HCC was based on histological results; * Patients must have at least one tumor lesion that can be accurately measured; * Not amendable to surgical resection ,local ablative therapy and any other cured treatment; * No Cirrhosis or cirrhotic status of Child-Pugh class A only; * No liver protection therapy in 2 weeks before enrolled, and meet the following laboratory parameters:(a) Platelet count ≥ 75,000/μL; (b)Hemoglobin ≥ 8.5 g/dL;(c) Total bilirubin ≤ 30mmol/L;(d) Serum albumin ≥ 32 g/L;(e) ASL and AST ≤ 5 x upper limit of normal;(f) Serum creatinine ≤ 1.5 x upper limit of normal;(g) INR \> 2.3 or PT/APTT within normal limits; (h) Absolute neutrophil count (ANC) \>1,500/mm3; * Ability to understand the protocol and to agree to and sign a written informed consent document
Exclusion criteria
* Evidence of hepatic decompensation including ascites, gastrointestinal bleeding or hepatic encephalopathy; * Known history of HIV; * History of organ allograft; * Known or suspected allergy to the investigational agents or any agent given in association with this trial; * Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy; * Any other hemorrhage/bleeding event \> CTCAE Grade 3 within 4 weeks of first dose of study drug.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free survival | 12 months | The period from the date of the start of HAIC or sorafenib until the date of the confirmation of tumor progression or death |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | 12 months | The period from the date of the start of HAIC or sorafenib until the date of the confirmation of tumor progression or death |
| Adverse Events | 30 Days after HAIC and TACE | Postoperative adverse events were graded based on CTCAE v4.03 |
| Objective response rate | 12 months | Best response based on mRECIST |
Countries
China
Outcome results
None listed